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Abstract 
We evaluated a new therapeutic strategy for malignant glioma, which combines 
intratumoral inoculation of mesenchymal stem cells (MSCs) expressing cytosine 
deaminase gene with 5-FC administration. For in vitro and in vivo experiments, MSCs 
were transfected with adenovirus carrying either enhanced green fluorescent protein 
gene (AdexCAEGFP) or cytosine deaminase gene (AdexCACD), to establish MSC 
expressing EGFP (MSC-EGFP) or CD (MSC-CD). Co-culture of 9L glioma cells with 
MSC-CD in a medium containing 5-FC resulted in a remarkable reduction in 9L cell 
viability. The migratory ability of MSC-EGFP towards 9L cells was demonstrated by 
double chamber assay. For the in vivo study, rats harboring 9L brain tumors were 
inoculated with MSC-EGFP or MSC-CD. Immunohistochemistry of rat brain tumors 
inoculated with MSC-EGFP showed intratumoral distribution of MSC-EGFP. Survival 
analysis of rats bearing 9L gliomas treated with intratumoral MSC-CD and 
intraperitoneal 5-FC resulted in significant prolongation of survival compared with 
control animals. In conclusion, molecular therapy combining suicide gene therapy and 
MSCs as a targeting vehicle represents a potential new therapeutic approach for 
malignant glioma, both with respect to the antitumor potential of this system and its 
neuroprotective effect on normal brain tissue. 
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Introduction 
Although conventional therapies for malignant glioma such as surgical resection, 
radiotherapy and chemotherapy are available, the prognosis for patients with this 
disease remains extremely poor 1. This can be traced back to the finding that malignant 
gliomas have the distinct ability to infiltrate the brain parenchyma and disrupt the neural 
extracellular matrix. Thus traces of the primary lesion frequently remain at the borders 
of the post-operative tumor cavity, eventually leading to tumor recurrence following 
initial treatment. Therefore, effective new therapeutic tools that specifically target the 
tumor cells, especially those cells that have escaped the main tumor mass are urgently 
needed 2.  
Current studies suggest that stem cells are effective delivery vehicles for gene 
therapy against malignant glioma 3-5. Work by Aboody et al. demonstrated that after 
intracranial injection, neural stem cells (NSCs) possess wide-ranging tropism for 
implanted glioma cells and show significant migratory behavior 3. Furthermore, 
Ehtesham et al. demonstrated that intracranial injection of NSCs engineered to express 
interleukin-12 or tumor necrosis factor-related apoptosis-inducing ligand exhibited 
strong antitumor effects in experimental glioma models 5. However, isolation of the 
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required amounts of autologous or allogeneic NSCs for clinical application is limited by 
technical barriers, ethical uncertainties and by issues with immunologic incompatibility. 
Recently, bone marrow stem cells, in particular mesenchymal stem cells 
(MSCs) have received much attention as an alternative source of neural progenitor cells 
for clinical application. Mesenchymal stem cells, which exist primarily in the bone 
marrow, can differentiate into osteoblasts, chondrocytes, adipocytes and hepatocytes 6, 7. 
Furthermore, in a rat cerebral ischemia model, MSCs have the ability to infiltrate from 
the initial intracranial injection site to the ischemic lesion 8, 9. Recently, it was reported 
that MSCs can migrate toward malignant glioma cells and that gene-transferred MSCs 
have the ability improve the survival of glioma-bearing mice 10, 11. These findings 
suggest that MSCs could act as surrogate NSCs and provide the vehicle for molecular 
therapy against glioma. Furthermore, the in vitro propagation of autologous MSCs for 
clinical use and implantation into patients with malignant glioma is not associated with 
the previously identified immunologic and ethical problems. 
The 5-fluorocytosine (5-FC)/Escherichia coli cytosine deaminase (CD) system 
is a suicide gene therapy system that is currently used for malignant tumors 12, 13. 
Expression of the CD gene within the target cell produces an enzyme that converts the 
prodrug, 5-FC, to the toxic metabolite, 5-fluorouracil (5-FU). The use of 
7 
 
5-fluorocytosine may be particularly suitable for brain tumors, because it can readily 
cross the blood-brain barrier (BBB). Since 5-FU is inhibitor of RNA synthesis, it is not 
toxic to nondividing normal neuronal cells. Moreover, gene therapy with 5-FC/CD also 
possesses a strong bystander effect that does not require direct cell-to-cell contact 13. In 
a recent study of mice bearing melanoma, it was reported that human MSCs expressing 
CD were associated with tumor regression 14. Thus, in the present study, we sought to 
evaluate the migratory ability of MSCs and the antitumor effects of 5-FC/CD gene 
therapy with MSC (5-FC/MSC-CD) as the targeting vehicle in vitro and in vivo models 
of glioma.  
 
Materials and methods 
Cell lines 
The 9L rat glioma cells and 293 cells (transformed human embryonic kidney cells) 
(JCRB9068, Health Science Research Resources Bank, Osaka, Japan) were maintained 
in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% 
heat-inactivated fetal bovine serum (FBS), 100 μg of streptomycin, and 100 U of 
penicillin. The 9L-DsR cells (9L cells labeled with Discosoma red fluorescent protein: 
DsRed2) were maintained in DMEM supplemented with 10% FBS and 800 μg/mL 
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G418. The cells were maintained at 37 °C in a humidified atmosphere of 5% CO2. 
 
Preparation of MSCs 
The MSCs were prepared from rat bone marrow as described previously 11. Briefly, 6 
week old male Fischer-344 rats (Clea Japan, Inc., Fuji Shizuoka, Japan) were 
euthanized with ketamine hydrochloride. The femurs and tibias were dissected free of 
soft tissue and the epiphyses were removed with scissors and the midshaft bone marrow 
tissue was flushed out into culture medium (DMEM supplemented with 10% FBS, 100 
U of penicillin, 100 μg of streptomycin). A single cell suspension was obtained by 
drawing the marrow into syringes through needles of sequentially decreasing size (18, 
20 and 22 gauge, respectively). The MSC primary cultures were seeded at a density of 
5×107 cells/10-cm dish. To remove the non-adherent cells, the medium was replaced 
with fresh medium 4 days after initial culture. The MSCs were maintained at 37 °C in 
5% CO2 by exchanging the spent medium with fresh medium at 4-day intervals.  
 
Preparation of recombinant adenovirus vectors and ex vivo gene transduction 
Two recombinant replication-deficient adenovirus vectors, AdexCAEGFP (containing 
the gene for enhanced green fluorescent protein, EGFP) and AdexCACD (containing 
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the CD gene) were constructed from a serotype-5 wild-type adenovirus (Ad5) by 
inserting the chicken alphaglobin promoter driving the E. coli EGFP gene or the E.coli 
CD gene into the E1 region of the genome. The E3 region of the adenovirus was deleted. 
The recombinant adenovirus vectors AdexCAEGFP and AdexCACD were prepared 
according to previously described methodology 13. The viral stocks were produced by 
infecting 293 cells with recombinant adenoviruses, purifying using CsCl 
density-gradient centrifugation and dialysis against phosphate-buffered saline (PBS) 
containing 10% glycerol. The stocks were stored at –80 °C. The viral titers were 
determined with an endpoint cytopathic effect assay on 293 cells and expressed as 
plaque forming units per milliliter (pfu). Purification of the AdexCAEGFP and 
AdexCACD viruses yielded concentrations of 1.0×1010 PFU/mL and 2.6×1010 PFU/mL, 
respectively. 
Ex vivo adenoviral gene transduction of primary MSCs was performed as described 
previously 11. Briefly, 1×106 MSCs were plated in 10-cm dishes 1 day before adenoviral 
infection. The cells were infected by incubation with 3 ml of stocked viral solution 
containing either 1000 pfu/cells of AdexCAEGFP or 20 pfu/cells of AdexCACD at 
37 °C in 5% CO2 for 8 hours. For the first 3 hours of the infection, the cells were shaken 
every half hour. Eight-hours after infection, the cells were supplemented with 7 ml of 
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normal medium and 48 hours after infection, the infected MSCs (MSC-CD, 
MSC-EGFP) were used for the experiments.  
 
CD enzyme activity assay 
To show whether AdexCACD vectors produce a functional CD enzyme, we selectively 
measured the concentration of 5-FU converted from 5-FC in the culture medium of 
MSC infected with the AdexCACD vectors. A total of 1×105 MSC were seeded in a 
6-well plate and infected with AdexCACD at a multiplicity of infection (MOI) of 20. 
After 24 hours, medium containing 5-FC (50–200 μg/mL) (Kyowa Yakuhin Co. Ltd, 
Wakayama, Japan) was added and maintained at 37 °C in 5% CO2. After 24 hours of 
incubation, the supernatant was collected and its 5-FU concentration was measured by 
high performance liquid chromatography (HPLC) 13. 
 
5-FC chemosensitivity of 9L cell co-cultured with AdexCACD-infected MSCs 
To evaluate the antitumor effect of the 5-FC/MSC-CD system in vitro, 9L-DsR cells 
were co-cultured with MSC-CD in medium containing 5-FC. The 9L-DsR cells (1×104 
cells) were plated into 24-well dishes along with increasing amounts of MSC-CD to 
produce ratios of MSC-CD to 9L-DsR cells of 0, 10, 25, 50, 100, and 200%. As a 
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control, MSC-EGFP was used at the same ratio as that of MSC-CD to 9L-DsR. At 24 
hours after the initial incubation, medium containing 5-FC (0 or 200 μg/mL) was added. 
This cell mixture was maintained in culture at 37 °C, 5% CO2 for 72 hours, and the 
percentage of surviving cells was then determined with the WST-8 assay (Cell Counting 
Kit, Dojindo Laboratories, Kumamoto, Japan). The DsRed2-positive 9L cells were 
evaluated by fluorescent microscopy. To confirm the bystander effect, which does not 
require cell-to-cell contact, a chemosensitivity assay was performed with a 
double-chamber dish with 0.4-μm pores (BD FALCON, Franklin Lakes, NJ). The 
MSCs were infected with AdexCACD at an MOI of 0-50. The 9L-DsR cells (1×103) 
were seeded into a 24-well multiwell dish. At 48 hours after infection, the MSC-CD 
(1×104) cells were seeded into a cell-culture insert (24-well format) with 0.4-μm pores. 
At 72 hours after infection, the cell-culture inserts of MSC-CD were placed in the 
multiwell dish with 9L-DsR in medium containing 5-FU (1.0 mmol/L) or 5-FC at 
various concentrations ranging from 0 to 1000 μmol/L. The cells were maintained at 
37 °C, 5% CO2 for 72 hours and the percentage of surviving 9L-DsR cells was then 
determined with a WST-8 assay. 
 
In vitro cell migration assay 
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The cell migration assay was performed in double-chamber culture dishes (BD 
FALCON, Franklin Lakes, NJ). The MSC-EGFP cells (5.0×104) were placed in the 
upper chamber with 8-μm pores, and the 9L cells (0, 2.5×104 and 2.5×105 cells) were 
placed in the lower well. The cell-culture inserts were placed at 37 °C, 5% CO2 for 24 
hours, then the number of MSC-EGFPs in the lower side in one high-power field by 
fluorescent microscopy were directly measured (40× magnification; Olympus; Tokyo, 
Japan) 11. Each experiment was done in triplicate. 
 
Intracerebral distribution of implanted MSCs 
To evaluate the intracerebral distribution of the MSCs, rats harboring 9L-DsR brain 
tumors were used for the experiment. Experimental animals were housed and handled in 
accordance with Okayama University Animal Research Committee guidelines. To 
establish the brain tumor model, 6-week old male Fisher-344 rats (Clea Japan, Inc.) 
(n=3) were anesthetized with intraperitoneal (i.p.) nembutal (30 mg/kg) and placed in a 
stereotactic apparatus (Narishige, Tokyo, Japan). The 9L-DsR cells (5×105 cells/5 μL) 
were slowly injected into the basal ganglia of the right cerebral hemisphere (3 mm 
lateral to the midline, 1 mm posterior to the coronal suture, 4 mm deep from the dura) 
with a Hamilton syringe (Hamilton, Reno, Nev, USA), according to previously 
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published procedures 13. Seven days after tumor inoculation, rats bearing brain tumors 
were re-anesthetized and received an intratumoral (i.t.) injection of MSC-EGFP (1×106 
cells/5 μL) or PBS only (control; 5 μl) according to the same stereotactic coordinates. 
At 14 days after tumor inoculation, the rats were perfused with PBS and 4% 
paraformaldehyde while under deep anesthesia. The excised brains were postfixed with 
4% paraformaldehyde overnight and then equilibrated in PBS containing 30% sucrose 
for 48 hours. The fixed brains were embedded in OTC (Sakura Fintek USA, Inc., 
Torrance, USA), snap frozen in liquid nitrogen and stored at –70 °C. The tissues were 
cryosectioned at 18-μm thickness and stained with hematoxylin and eosin (H&E) or 
with an anti-GFP monoclonal antibody (Medical & Biological Laboratories Co. Ltd, 
Nagoya, Japan). The sections stained with the first antibody were visualized with a 
Vectastain kit obtained from Vector Laboratories (Burlingame, CA, USA). The images 
were acquired with a fluorescent microscope (Biorevo BZ-9000, Keyence, Osaka, 
Japan). 
 
The antitumor effect of the 5-FC/MSC-CD system in vivo 
To assess the antitumor effect of the 5FC/MSC-CD system in vivo, 5.0 ×105 9L cells 
mixed with an equal quantity of MSC-CD cells or MSC-EGFP cells (control) were 
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implanted subcutaneously into the right flanks of 6–8 week old nude mice (balb/c- 
nu/nu, CLEA Japan, Inc, Tokyo, Japan). The mice had a median weight of 20 grams. 
The mice were treated i.p. with 5-FC (500 mg/kg) or PBS (control) 48 hours after tumor 
implantation. This treatment was repeated once a day for 2 weeks. Tumor length, height 
and width were measured two times per week with calipers by a researcher blinded to 
each animal’s treatment group. 
We also evaluated the antitumor effect of MSC-CD in rats harboring 9L brain 
tumors. To establish the brain tumor model, the 9L-DsR cells (5×105 cells/5 μL) were 
slowly injected into the right basal ganglia (3 mm lateral to the midline, 1 mm posterior 
to the coronal suture, 4 mm deep from the dura) of Fisher-344 rats. Five days after 
tumor inoculation, rats bearing brain tumors were re-anesthetized and received an 
intratumoral injection of MSC-CD or MSC-EGFP (1×106 cells/5 μL) or PBS only 
(control; 5 μl) according to the same stereotactic coordinates. Treatment with i.p. 5-FC 
(500 mg/kg) or PBS (control) was commenced 48 hours after injection of the MSC and 
repeated once a day for 2 weeks. The animals were monitored and sacrificed near death, 
and survival analysis was conducted.  
 
Statistical analysis 
15 
 
The data are expressed as the mean ± standard deviation. The chemosensitivity, in vitro 
migration ability, and the size of flank tumor in each group was compared using a 
one-way ANOVA followed by a Scheffé’s post hoc test. Kaplan – Meier curves were 
compared using the log-rank test. All statistical tests were two-sided. A P-value of less 
than 0.05 was considered significant. All statistical analyses were performed with the 
use of SPSS statistical software (version 14.0; SPSS, Inc., Chicago, IL). 
 
Results 
CD enzyme activity 
The conversion of 5-FC to 5-FU was measured by HPLC after 24 hours of incubation. 
The concentration of 5-FU increased in a dose-dependent fashion in the supernatant of 
the medium containing MSCs infected with the AdexCACD vector, with 1.84, 2.92, 
5.42μg/ml of 5-FU concentration when the medium containing 50, 100, 200μg/ml of 
5-FC, respectively. Data are expressed as 5-FU concentration in the supernatant relative 
to the 5-FC added in the culture medium (Figure 1). 
 
The antitumor and bystander effects of the 5-FC/MSC-CD system in vitro  
To evaluate the antitumor effect of the 5-FC/MSC-CD system in vitro, the 9L-DsR cells 
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were co-cultured with MSC-CD or MSC-EGFP in medium with or without 5-FC. The 
number of DsRed-positive cells was determined. As shown in Figure 2, the proliferation 
of 9L-DsR cells was significantly inhibited by co-culture with only 10% MSC-CD in 
the medium containing 5-FC relative to the control medium. Next, to confirm that the 
bystander effect did not require cell-to-cell contact, a chemosensitivity assay was 
performed using double-chamber dish. The MSCs were infected with AdexCACD at an 
MOI of 0–50 (Figure 3). A marked, dose-dependent suppression of 9L-DsR cell growth 
in the medium with 5-FC was observed, regardless of the MOI (10, 20, 50). There was 
no statistical difference in growth suppression between either MOI at any 
concentrations of 5-FC. 
 
Migratory ability of MSCs in vitro  
The migratory nature of MSC towards glioma cells was evaluated by double-chamber 
assay in vitro. Although the MSC-EGFP did not migrate without 9L cells in the lower 
chamber, they were stimulated to migrate by the addition of 9L cells into the lower 
chamber. Of the MSC-EGFP (5.0×104 cells) placed in the upper chamber, 9.0% 
(4.5×103 cells) moved to the lower side in the presence of 2.5×104 9L cells. In contrast, 
38% (1.9×104 cells) moved to the lower side in the presence of 2.5×105 9L cells. The 
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migration of MSCs increased in a dose-dependent manner with increasing numbers of 
9L cells (P < 0.005) (Figure 4A and 4B). 
 
Intracerebral distribution and tumor tropism of implanted MSC 
After the confirmation of the in vitro migratory ability of MSCs, we investigated 
whether implanted MSCs could migrate toward an intracranial glioma in vivo. The 
9L-DsR glioma cells were inoculated into the right basal ganglia, and the MSC-EGFP 
were injected directly into the glioma 7 days later. The rats (n=3) were sacrificed 14 
days after tumor inoculation and the brain sections were prepared. The EGFP-labeled 
MSCs infiltrated into the established tumor in a relatively uniform manner (Figure 5A). 
Moreover, the GFP-labeled MSCs were densely localized at the border between the 
tumor and normal parenchyma. By fluorescent microscopy, the GFP-labeled MSCs, 
most of which retained their spindle-like shape, infiltrated into the DsRed-labeled 9L 
tumor (Figure 5B). Additionally, the MSCs were observed around the glioma cells, 
which spread out from the main tumor (Figure 5C). By fluorescent microscopy, no 
GFP-positive MSC was observed in distal brain parenchyma where no DsRed-labeled 
9L tumor cell invaded. Similar distribution of MSC was observed in all animals. Thus, 
the MSCs demonstrated significant migratory capability and glioma tropism in the 
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established in vivo tumor model. 
 
In vivo antitumor effect of the 5-FC/MSC-CD system 
The antitumor efficacy of 5-FC/MSC-CD was tested on subcutaneous tumors in 
athymic mice. The 9L cells mixed with MSC-CD or MSC-EGFP (control) were 
implanted subcutaneously into the right flanks of athymic mice. The mice harboring 
subcutaneous tumors (150–250 mm3) were treated i.p. with 5-FC (5-FC/MSC-CD), 
while the control animals were treated i.p. with 5-FC (5-FC/MSC-EGFP) or PBS 
(PBS/MSC-EGFP). The animals were closely monitored for tumor growth. Figures 6A 
and B shows the tumor growth of individual mice from the groups treated with 
PBS/MSC-EGFP (top panel), 5-FC/MSC-EGFP (middle panel) and 5-FC/MSC-CD 
(bottom panel). All mice treated with i.p. PBS rapidly developed subcutaneous tumors. 
There was a significant difference in tumor size in mice treated with 5-FC/MSC-CD 
compared with those treated with PBS/MSC-EGFP or 5-FC/MSC-EGFP. 
Survival of the rats bearing the 9L gliomas treated with 5-FC/MSC-CD were 
also analyzed (Figure 7). Control rats treated with PBS/PBS and PBS/MSC-EGFP had 
both median survivals of 28 days after tumor cell implantation. The rats treated with 
PBS/MSC-CD and 5FC/MSC-EGFP had median survivals of 31 and 31.5 days after 
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tumor cell implantation, respectively. Compared with the animals treated with 
5-FC/MSC-EGFP, those treated with 5-FC/MSC-CD had a significantly prolonged 
survival (31 days versus 44 days, log-rank P < 0.001). In the control groups, there was 
little difference in the survival of the animals treated with PBS/PBS compared with 
other control groups. No systemic toxicity due to 5-FC was observed when the rats were 
treated with i.p. injections of 5-FC at 500 mg/kg/day for 14 days without intracerebral 
injection of 9L rat glioma cells (data not shown). 
 
Discussion 
Glioma tropism of MSC 
In this study, we demonstrated that MSCs have the ability to migrate towards glioma 
cells in vitro and in vivo. While our study was subjected by using rat MSCs and rat 
glioma cell line, the migratory activity of MSCs was demonstrated in human cell lines 
similarly. Park et al. reported that human umbilical cord blood-derived MSCs 
(hUCB-MSCs) were able to migrate toward the human glioma cell lines (U-87MG, 
U-251MG, three primary glioma cell lines)15. These results suggested that soluble 
factors released from 9L glioma cells were responsible for the tropism of the MSCs for 
the glioma cells. This is in agreement with previous reports, which suggest that soluble 
20 
 
factors, or chemoattractants, may include various chemokines, cytokines and growth 
factors. For example, platelet-derived growth factor (PDGF-BB), epidermal growth 
factor (EGF) and vascular endothelial growth factor (VEGF-A) have all been shown to 
enhance tumor tropism of MSCs 10, 16. Birnbaum et al. reported that the tumor tropism 
of MSCs is dependent on interleukin-8 (IL-8), transforming growth factor-β1 (TGF-β1) 
and neurotropin-3 (NT-3) 17. In comparison, Xu et al. reported that monocyte 
chemoattractant protein-1 (MCP-1) and stromal-cells derived factor-1 alpha (SDF-1α) 
play a role in migration of MSCs toward gliomas 18. Furthermore, Park et al. reported 
that overexpression of the SDF-1α receptor, CXCR4, on hUCB-MSCs enhanced the 
migratory capacity of MSCs toward gliomas 15. In addition, it has been suggested that 
MSC migration requires extracellular matrix (ECM) as the toehold. To this end, 
Schichor et al. reported that laminin and tenascin were involved in MSC migration 16. In 
fact, it has been reported that laminin, tenascin, fibronectin, vitronectin and different 
types of collagen are upregulated within the glioma stroma and at the advancing edge of 
the tumor within the brain parenchyma 19, 20. 
 
Advantages of MSCs as a glioma-targeting vehicle 
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Despite the genetic heterogeneity of malignant gliomas, common aberrations in the 
signaling elements involved in their angiogenesis and invasion pathways are known 
to exist 21. Although anti-VEGF therapy (e.g., bevacizumab) seems to be effective in 
normalizing abnormal tumor vasculature, leading to an enhanced response to 
radiation and chemotherapy, tumors eventually become resistant to the therapy and 
adopt a highly infiltrative and invasive phenotype. Therefore, it is important to 
develop a therapeutic option with the ability to track the tumor cells and coupled with 
one that has multiple mechanisms through which the antitumor activity can occur. 
There are several advantages of MSCs as a targeting vehicle for malignant glioma. 
As shown by our experiments, MSCs show active in situ targeting capabilities 
toward invading glioma cells, whereas conventional antitumor agents including 
chemotherapeutic drugs and viral vectors have only passive distributive effects after 
administration. Findings by Nakamura et al showed the intracranial distribution of 
MSCs resembled capsule-like structures around the tumor mass 11. This unique 
intracranial distribution of MSCs might act as a barrier preventing the spread of 
glioma cells into the normal parenchyma. Recently, findings suggest that MSCs 
secrete large amounts of angiogenic factor angiopoietin-1 (Ang1) 22. Coupled to this 
is the knowledge that Ang1 can inhibit tumor-vascular leakage and also tumor 
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growth in vivo. Therefore, Ang1 released from MSCs could represent an additional 
antitumor effect of MSC. Moreover, other neurotrophic factors are released from 
MSCs, including nerve growth factor (NGF) 23, which can induce the differentiation 
and the growth-inhibition of C6 glioma cells in vitro. This may act as a potential 
mechanism underlying the antitumor effect exerted by MSCs 24. In the cerebral 
infarction model, it has been reported that implanted MSCs mediate neural protection 
through the inhibition of neuronal apoptosis and this protective effect is thought to be 
because neurotrophic factors such as NGF, are released from the MSCs 23. Therefore, 
the implantation of MSCs for the treatment of gliomas might be beneficial both with 
respect to its antitumor potential and its protective effect on normal brain tissues. 
 
Application of genetically engineered-MSCs for malignant glioma 
Our results add to the list of applications for MSCs that have been presented to date. 
Previous studies have shown that the genetic manipulation of MSCs, either by 
overexpressing targeting molecules or by introducing exogenous genes for the 
expression/secretion of a desired therapeutic factor, have the ability to improve the 
migratory efficiency to specific tumor cells and enhance the antitumor effect of MSCs. 
Nakamura et al. reported antitumor effect of genetically engineered MSC expressing 
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human IL-211. Their findings showed prolonged survival in rats bearing 9L brain tumors 
when treated with MSCs expressing IL-2 compared to those treated with unmodified 
MSCs. Therefore in this study, IL-2 gene modification of MSCs conferred additional 
therapeutic benefits. Chen et al 25. transduced MSCs with an adenovirus engineered to 
secrete interleukin-12. Human MSCs, engineered to express interferon-β (IFN-β), have 
been used for targeted delivery of IFN-β, a potent antiproliferative and proapoptotic 
agent, in both metastatic 26 and gliomas 10 models. Studies have also shown the 
antiproliferative, antitumor and immunomodulatory effects of IFN-α 27, a 
multifunctional regulatory cytokine. Mohr et al. reported the ability of an adenoviral 
vector expressing TRAIL to transduce MSCs and the subsequent therapeutic efficacy of 
these MSCs in a lung cancer model 28. The potential of mesenchymal progenitor cells to 
assist the delivery of an oncolytic virus which targets virus-mediated lysis of tumor cells 
has been evaluated and may be a novel approach for human glioma therapy 29-32.  
 
Suicide-gene transferred-MSC for malignant glioma 
In our therapeutic system, the 5-FC/CD suicide gene therapy was found to exert its 
antitumor effect mainly via a bystander effect. The CD gene-transferred MSCs 
navigated to the glioma cells among the normal brain parenchyma, and the conversion 
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of 5-FC into 5-FU by the CD gene in the vicinity of the migrated glioma cells can 
impair these single tumor cells. The strong bystander effect of the 5FC/MSC-CD system 
means that tumor regression is possible using nontoxic levels of 5-FC, even if only a 
small percentage of MSCs expresses CD. Amano et al. reported that GCV/HSVtk gene 
therapy combined with MSCs was effective in the treatment of rat glioma 33. In that 
system, however, the bystander effect of GCV/HSVtk gene therapy required direct 
cell-to-cell contact and was depended upon the formation of gap junctions between 
contact cells and upon the expression of connexin-43 in the cells 34. In contrast, the 
bystander effect of 5-FC/CD gene therapy does not require direct cell-to-cell contact 10, 
13. Therefore, invasive glioma cells may become extensively disordered if MSCs reach 
the vicinity of tumor cell. 
 
Future perspectives 
Although treatment with the 5-FC/MSC-CD system was shown to be effective for the 
highly invasive malignant glioma, hurdles must be overcome before this therapeutic 
system could be implemented. First, the experiments conducted in this study were 
performed in a small animal model. Nevertheless, the capacity of MSCs to migrate 
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through the brain parenchyma suggests that these cells can survive within the CNS for a 
prolonged period of time, a prerequisite condition for use of human MSCs within the 
much larger human brain. Primate study is desirable before clinical application. Second, 
the available volume of autologous MSCs is limited. Although our studies have focused 
on bone marrow–derived MSCs, recent work suggests that other cells in the bone 
marrow, such as the marrow-derived neural-competent cell (MDNCC), may also be a 
useful delivery vehicle for brain tumors 35. Third, preclinical data and the results of 
early patient trials with cell-based gene therapy suggest that the generation of secondary 
malignancies is a potential risk 36, 37. In our system, tumorigenic transformation of 
MSCs may be avoided because the MSCs themselves, in theory, are killed by the 5-FU. 
 
Conclusions 
In this study we demonstrated the tumor homing capabilities and antitumor effects of 
the 5-FC/MSC-CD system in vitro and in vivo. This system demonstrated a potent 
bystander effect with the ability to kill tumor cells even when the MSCs and tumor 
cells were not in direct contact leading to the invading glioma cells becoming 
extensively disordered. This system may represent a promising new therapeutic 
approach for highly invasive malignant glioma. 
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Figure legends 
Figure 1. The conversion of 5-FC to 5-FU mediated by cytosine deaminase (CD) in 
vitro  
The MSCs were infected with AdexCACD at an MOI of 20 and treated with 5-FC. The 
concentration of 5-FU in the supernatant increased in a dose-dependent manner, with 
1.84, 2.92, 5.42μg/ml of 5-FU concentration when the medium containing 50, 100, 
200μg/ml of 5-FC, respectively. 
 
Figure 2. The antitumor and bystander effects of the 5-FC/MSC-CD system in vitro 
The 9L-DsR cells were co-cultured with MSC-CD or MSC-EGFP in medium with or 
without 5-FC, and the number of DsRed-positive cells was then determined. The 
proliferation of 9L-DsR co-cultured with MSC-CD in media containing 5-FC was 
significantly inhibited (MSC-CD/5FC(+)) (mean ± SD, n = 4).  
 
Figure 3. Validating the bystander effects of the 5-FC/MSC-CD system in vitro  
To confirm that the bystander effect does not require cell-to-cell contact, a 
chemosensitivity assay was performed in a double-chamber dish. Proliferation of 
9L-DsR cells in the lower chamber was inhibited significantly when the MCS-CD cells 
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were cultured in the upper chamber with medium containing 5-FC (mean ± SD, n = 
4). 
 
Figure 4. Migratory ability of MSCs in vitro  
A: MSC-EGFPs in the upper chamber were stimulated to migrate to the lower chamber 
by the addition of 9L cells into the lower chamber. The number of migrated MSCs 
increased in a dose-dependent manner with increasing numbers of 9L cells (*P = 0.0012, 
**P = 0.0005) (mean ± SD, n = 3). B: A fluorescent microscopic view of the migrated 
MSC-EGFPs in the lower chamber. Magnification, ×40. 
 
Figure 5. Intracranial distribution and tumor tropism of implanted MSCs 
The MSC-EGFP cells were injected at the center of the 9L-DsR brain tumor. The rats 
were sacrificed and their brains were excised 7 days after the MSC injection.  
A: Macroscopic photograph of immunostaining with anti-GFP monoclonal antibody. 
The GFP-positive MSCs (brown) infiltrated into the established tumor in a relatively 
uniform manner. The GFP-labeled MSCs were densely localized at the border between 
the tumor and normal parenchyma. Scale bar = 1mm. 
B, C: Immunofluorescence microscopy showing the border zone between the 
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DsRed-labeled 9L tumor (red) and normal parenchyma (B) and the invading tumor cells 
in the normal brain parenchyma (C). The GFP-labeled MSCs (green), most of which 
retained their spindle-like shape, accumulated in the tumor border zone (B), although 
some tracked, or navigated, to the tumor cells adjacent to the main mass (C). Scale bar = 
100 μm. 
 
Figure 6. In vivo antitumor effects of the 5-FC/MSC-CD on mice subcutaneous 
tumors 
A: 9L cells mixed with MSC-CD or MSC-EGFP (control) were implanted 
subcutaneously into the right flanks of nude mice. The mice were treated with i.p. 5-FC 
or PBS. There was a significant difference in tumor size in the mice treated with 
5-FC/MSC-CD compared with those treated with 5-FC/MSC-EGFP and 
PBS/MSC-EGFP (P < 0.005) (mean ± SD, n = 4).  
B: Representative figure showing the size of subcutaneous tumors in the anesthetized 
mice. At 35 days after tumor inoculation, significant growth suppression was observed 
in mice treated with 5-FC/MSC-CD (bottom panel) compared with those treated with 
PBS/MSC-EGFP (top panel) and 5-FC/MSC-EGFP (middle panel).  
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Figure 7. Survival analysis of rats bearing the 9L brain tumors  
Rats bearing 9L brain tumors were divided into five treatment groups; PBS/PBS, 
PBS/MSC-EGFP, PBS/MSC-CD, 5-FC/MSC-EGFP and 5-FC/MSC-CD. Compared 
with animals treated with PBS/PBS, PBS/MSC-EGFP, PBS/MSC-CD and 
5-FC/MSC-EGFP, those treated with 5-FC/MSC-CD had a significantly prolonged 
survival (44 days, log-rank P < 0.001). 
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